Regeneron will temporarily extend physician payment terms for Eylea injection purchases for 150 days in response to the COVID-19 pandemic, the American Academy of Ophthalmology announced in a press release.
The new payment terms would extend the previous 100-day term, subject to distributor qualification. The company plans to implement the new terms by April 1 and have them apply to Eylea (aflibercept) retroactively to March 1, the release said.
“The COVID-19 pandemic is having a significant impact on patients and ophthalmologists. In some cases, it is limiting patient access to essential